Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

JNJ 105.55 -1.26 (-1.18%)
price chart
Johnson & Johnson Prostate Cancer Drug Impresses
A new study shows that Johnson & Johnson's prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy.
Related articles »  
Johnson and Johnson's Synthes Deal Revives Foreign Tax Debate
After receiving regulatory clearance for its $19.7 billion acquisition of Swiss medical device maker Synthes, Johnson & Johnson says the mega-deal will add to earnings per share after previously forecasting dilution: All with the help of bankers ...
Johnson & Johnson Announces Completion of Synthes Acquisition  PR Newswire (press release)
Related articles »  
Johnson & Johnson's Favorable Ratings: Does The Market Prefer Trademarks ...
Analysts are starting to like Johnson & Johnson again. (Disclaimer: I have now exhausted my knowledge of markets.) What drives the value of companies these days, brand power (trademarks) or brain power (patents)?
Johnson & Johnson Should Split Up Says Goldman
Johnson & Johnson should split into three companies, which could value health-care conglomerate at $76 a share, up more than 20% from current price of $62, Goldman Sachs says.
Related articles »  
Johnson & Johnson Latest Company To Break Away From ALEC
Johnson & Johnson is the latest company to break away from the American Legislative Exchange Council (ALEC). On June 12, Johnson & Johnson announced it would stop funding the group that has pushed states to pass voter ID and stand-your-ground ...
Johnson & Johnson a Top Ranked SAFE Dividend Stock With 3.7% Yield
Johnson & Johnson (NYSE: JNJ) has been named to the Dividend Channel �S.A.F.E. 25� list, signifying a stock with above-average �DividendRank� statistics including a strong 3.7% yield, as well as a superb track record of at least two decades of dividend ...
Related articles »  
Johnson & Johnson is seeking a Design Research Manager in New York, New ...
The J&J Cross-Sector Innovation and Design team was created about five years ago to help J&J develop more leading-edge designs for both consumer products and medical devices.
Johnson & Johnson Reserves Funds for Settlement
Johnson & Johnson said Friday that it would add about $600 million to its reserves to cover a possible settlement of allegations that it paid kickbacks to a company that dispenses drugs to nursing homes.
Related articles »  
Johnson & Johnson a Top 25 Dividend Giant With 3.89% Yield
Johnson & Johnson (NYSE: JNJ) has been named as a Top 25 �Dividend Giant� by ETF Channel, with a whopping $3.44B worth of stock held by ETFs, and above-average �DividendRank� statistics including a strong 3.89% yield, according to the most recent ...
Related articles »  
Looking at Johnson & Johnson's Intangibles
Johnson & Johnson (NYS: JNJ) carries $34.5 billion of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down the road.
Related articles »